UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

Investigational new drugs, 2012-06, Vol.30 (3), p.1216-1223

2012

Volltextzugriff (PDF)

Reply to A. Soultati et Al

Journal of clinical oncology, 2014-11, Vol.32 (33), p.3781-3782

2014

Volltextzugriff (PDF)

Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

Investigational new drugs, 2012-06, Vol.30 (3), p.1272-1273

2012

Volltextzugriff (PDF)

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines

The women's oncology review, 2004-03, Vol.4 (1), p.47-47

Spigel, David Robert

2004

Volltextzugriff (PDF)

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines

The women's oncology review, 2004-01, Vol.4 (1), p.47-47

Spigel, David Robert

2004

Volltextzugriff (PDF)

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

The New England journal of medicine, 2018-12, Vol.379 (24), p.2342-2350

2018

Volltextzugriff (PDF)

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

The lancet oncology, 2019-04, Vol.20 (4), p.518-530

2019

Volltextzugriff (PDF)

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

Journal of thoracic oncology, 2018-05, Vol.13 (5), p.682-688

2018

Volltextzugriff (PDF)

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153

Journal of clinical oncology, 2020-11, Vol.38 (33), p.3863-3873

2020

Volltextzugriff (PDF)

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

The New England journal of medicine, 2012-06, Vol.366 (26), p.2443-2454

2012

Volltextzugriff (PDF)

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4105-4114

2013

Volltextzugriff (PDF)

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-06, Vol.29 (18), p.2582-2589

2011

Volltextzugriff (PDF)

Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma

Journal of clinical oncology, 2010-05, Vol.28 (13), p.2131-2136

2010

Volltextzugriff (PDF)

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

Journal of thoracic oncology, 2015-01, Vol.10 (1), p.S1-S63

2015

Volltextzugriff (PDF)

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

Journal of clinical oncology, 2009-02, Vol.27 (5), p.672-680

2009

Volltextzugriff (PDF)

International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1

Journal of clinical oncology, 2012-08, Vol.30 (23), p.2829-2836

2012

Volltextzugriff (PDF)

High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History

Journal of clinical oncology, 2007-08, Vol.25 (24), p.3644-3648

2007

Volltextzugriff (PDF)

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

Journal of clinical oncology, 2014-12, Vol.32 (35), p.4012-4019

2014

Volltextzugriff (PDF)

Advances in molecular‐based personalized non‐small‐cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

Cancer medicine (Malden, MA), 2015-11, Vol.4 (11), p.1621-1632

2015

Volltextzugriff (PDF)

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

Journal of clinical oncology, 2010-05, Vol.28 (15), p.2598-2603

2010

Volltextzugriff (PDF)

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Annals of oncology, 2020-06, Vol.31 (6), p.745-759

2020

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(75)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(30)
Oncology
(28)
Humans
(25)
Female
(22)
Male
(21)
Lung Neoplasms - Drug Therapy
(18)
Middle Aged
(18)
Adult
(17)
Aged
(17)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(15)
Aged, 80 And Over
(13)
Tumors
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Treatment Outcome
(10)
Chemotherapy
(9)
Disease-Free Survival
(8)
Lung Neoplasms - Pathology
(8)
Biological And Medical Sciences
(7)
Carboplatin - Administration & Dosage
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

Reply to A. Soultati et Al

Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

Advances in molecular‐based personalized non‐small‐cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Suchergebnisse filtern